Chronic myeloid leukaemia

Link to article at PubMed

Lancet. 2021 Aug 20:S0140-6736(21)01204-6. doi: 10.1016/S0140-6736(21)01204-6. Online ahead of print.


Tyrosine-kinase inhibitors have changed the natural history of chronic myeloid leukaemia in such a way that patients with adequate access to these agents, who are properly managed, and who respond well to this treatment can expect a near-normal life expectancy. Achieving this goal requires an adequate understanding of the patient's treatment goals, careful monitoring for the achievement of optimal response hallmarks, implementation of proper interventions according to the attainment of such endpoints, adequate recognition and management of adverse events, and acknowledgment of the relevance of comorbidities. Treatment with tyrosine-kinase inhibitors, once considered lifelong, has become terminable for at least some patients, and promising new agents are emerging for those whose disease does not respond to any of the multiple therapeutic options currently available. If these advances reach all patients with chronic myeloid leukaemia, cure might eventually become a reality in most instances.

PMID:34425075 | DOI:10.1016/S0140-6736(21)01204-6

Leave a Reply

Your email address will not be published.